{"id":1013294,"date":"2026-10-25T12:04:28","date_gmt":"2026-10-25T16:04:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/"},"modified":"2026-10-25T12:04:28","modified_gmt":"2026-10-25T16:04:28","slug":"oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/","title":{"rendered":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MENLO PARK, Calif., Oct.  25, 2026  (GLOBE NEWSWIRE) &#8212; Oruka Therapeutics, Inc. (\u201cOruka\u201d) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.<\/p>\n<p>\n        <strong><br \/>\n          <em>Webcast Details <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"left\">Oruka Therapeutics\u2019 live webcast of the EVERLAST-B results will begin on Monday, October 26<sup>th<\/sup>, at 8:00 a.m. ET. The live webcast can be accessed via this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gPKFSoN36jb9fWqRsShq9q6sz5a_ZPEVscyUAsuq1lXRwuS_k5dV7YHhWmaCt80RLRPFXFiH-63P0WorK7-WPQu-fN8_DbANqD88yHOHzDI=\" rel=\"nofollow\" target=\"_blank\">link<\/a>, or through the Investors section on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zXunqt8b6X_BGlpGYNmBFmjNzGSuDr1II7aGY3vt9hXhmtu-F3n57wGwU059IOTVi1o_wD5P5r-beVmrFc6SBUYnZ-oV-ZNHoJpp_HxNQPU9W8Zg_Yz6O6tIzj5BUr7OKiDKZYpf8TLCu3_CzAL1HnwQ6XyKGMsc62akUA0r1ZyF_ureM3UHngPSLX6jopdJ\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.orukatx.com\/news-events\/events-presentations<\/a>. A replay of the webcast will be available following the call.<\/p>\n<p>\n        <strong>About Oruka Therapeutics<\/strong>\n      <\/p>\n<p>Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka\u2019s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qw9C1e9bFRiR_O7D0T_55qA2bvGreJXCuPy6Qtm5WztZrVspsLLbMdo_8LpwOZmBrahQlWX520zwCRYPWGblVjMinIVB2KMyZO8cO7N2UEU=\" rel=\"nofollow\" target=\"_blank\">www.orukatx.com<\/a> and follow Oruka on LinkedIn.\u00a0<\/p>\n<p>\n        <strong>Investor Contact:\u00a0<\/strong><br \/>\n        <br \/>Alan Lada\u00a0<br \/>(650)-606-7911\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_b9LlfaprS3FsXyJ0tT1bsZNcAkw99W2013jstQXl6GLNiOHFZaH3I7I9CchcmtgykoVuAl34Lh75XpMQ1YzIpo8iUckuM56XfFua8z9V6A=\" rel=\"nofollow\" target=\"_blank\">alan.lada@orukatx.com<\/a>\u00a0 \u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmY1NWY2NjMtMTllNy00MWU2LThiYzMtYjMwYzg3NGMzNDc0LTEzMDE2NDktMjAyNi0xMC0yNS1lbg==\/tiny\/Oruka-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) &#8212; Oruka Therapeutics, Inc. (\u201cOruka\u201d) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics\u2019 live webcast of the EVERLAST-B results will begin on Monday, October 26th, at 8:00 a.m. ET. The live webcast can be accessed via this link, or through &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013294","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) &#8212; Oruka Therapeutics, Inc. (\u201cOruka\u201d) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics\u2019 live webcast of the EVERLAST-B results will begin on Monday, October 26th, at 8:00 a.m. ET. The live webcast can be accessed via this link, or through &hellip; Continue reading &quot;Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-25T16:04:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026\",\"datePublished\":\"2026-10-25T16:04:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/\"},\"wordCount\":245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/\",\"name\":\"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\",\"datePublished\":\"2026-10-25T16:04:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/","og_locale":"en_US","og_type":"article","og_title":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk","og_description":"MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) &#8212; Oruka Therapeutics, Inc. (\u201cOruka\u201d) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics\u2019 live webcast of the EVERLAST-B results will begin on Monday, October 26th, at 8:00 a.m. ET. The live webcast can be accessed via this link, or through &hellip; Continue reading \"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-25T16:04:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026","datePublished":"2026-10-25T16:04:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/"},"wordCount":245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/","name":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=","datePublished":"2026-10-25T16:04:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MjU2NyM3OTE0NTAxIzIyOTAwOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013294"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013294\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}